Company intelligence / Profile preview

Nuvation Bio

New York, New York, United Statesnuvationbio.com ↗

Ownership: Public · NUVB
Development stage: NDA

Overview

Taletrectinib (3rd generation ROS1 inhibitor) is approved in China for advanced ROS1+ NSCLC and under FDA priority review in the US with PDUFA date of June 23, 2025. Safusidenib (brain-penetrant IDH1 inhibitor) is entering pivotal studies for diffuse IDH1-mutant glioma. NUV-1511 (drug-drug conjugate) is in Phase 1/2 studies. NUV-868 (BD2-selective BET inhibitor) has completed Phase 1 and Phase 1b studies.[4][5]

Therapeutic areas: Oncology
Modalities: Small moleculesDrug-drug conjugates (DDC)
Industry: Biotech

Drug pipeline

10 assets

taletrectinib

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Daiichi Sankyo (taletrectinib licensing)Sagard Healthcare Partners (financing)

Financials

Market cap: $2.3B
Total revenue: $31.7M
Enterprise value: $1.9B

Beyond the preview

Go deeper on Nuvation Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuvation Bio.

Explore the full profile